More than 71% of patients treated with Unloxcyt achieved disease control
Category: News
The firm already has a number of offices across the UK and Europe
The collaboration will help to advance a pipeline of antibody candidates
Company prepares marketing submission after treatment shows strong efficacy
Decision introduces zolbetuximab for eligible patients in NHS Scotland
Dysport reduces muscle contractions by blocking the transmission of nerve impulses
Acquisition expands PMGroup’s commitment to transforming workplace health and organisational resilience
Regulator accepts supplemental application supported by positive phase 3 data
Investment to accelerate development of full‑format antibody capabilities on eProtein Discovery system
New manufacturing technologies aim to accelerate next-generation cell therapy development